Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Portfolio Pulse from Avi Kapoor
U.S. stocks surged with the Nasdaq Composite gaining over 200 points. The Dow and S&P 500 also saw gains. Information technology shares climbed, while energy shares fell. U.S. producer prices rose 0.1% in July. Notable stock movements included Vicinity Motor Corp. (VEV) up 154%, CXApp Inc. (CXAI) up 92%, and Apollomics, Inc. (APLM) up 41%. Syros Pharmaceuticals, Inc. (SYRS) dropped 59%, Genprex, Inc. (GNPX) fell 32%, and TELA Bio, Inc. (TELA) fell 30%.
August 13, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apollomics, Inc. shares rose 41% after announcing preliminary data and a 43% response rate for its phase 2 SPARTA trial of Vebreltinib.
Positive clinical trial data has likely increased investor optimism, resulting in a significant rise in APLM's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
CXApp Inc. shares surged 92% after announcing a deal and multi-year agreement with Google Cloud.
The announcement of a significant deal with Google Cloud has likely boosted investor confidence, leading to a sharp rise in CXAI's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Vicinity Motor Corp. shares surged 154% after a significant dip on Monday.
The sharp increase in VEV's stock price indicates a strong recovery and positive investor sentiment following a previous dip.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Genprex, Inc. shares fell 32% after being granted a patent in Singapore for Reqorsa Gene Therapy in combination with PD-1 antibodies.
Despite the patent grant, the market reaction was negative, possibly due to other underlying concerns or unmet expectations.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Syros Pharmaceuticals shares dropped 59% after announcing it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial.
The decision to discontinue a clinical trial is a significant negative development, leading to a sharp decline in SYRS's stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
TELA Bio, Inc. shares fell 30% after reporting worse-than-expected second-quarter financial results.
The disappointing financial results have likely led to a significant decline in TELA's stock price as investors react to the negative earnings report.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80